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Abstract Many patients elect to have repeat treatments
with hyaluronic acid dermal ﬁllers to maintain wrinkle
correction, but the clinical performance of these products
after repeat treatments has not been formally assessed. The
primary objective of this study was to evaluate the effec-
tiveness of Juve ´derm injectable gel (Juve ´derm Ultra,
Juve ´derm Ultra Plus, and Juve ´derm 30) through 1 year after
repeat treatment of nasolabial folds (NLFs) that were pre-
viously treated with Juve ´derm or Zyplast 6–9 months prior
to the repeat treatment. Upon completion of the pivotal
IDE clinical trial for Juve ´derm, ﬁve of the original 11 study
sites were selected to participate in an extended follow-up
evaluation, and a total of 80 subjects were enrolled. For the
Juve ´derm-treated NLFs in each treatment group, the
median injection volume was 1.5–1.6 mL for initial
treatment but only 0.5–0.6 mL for the repeat treatment
(p\0.0001). Mean Investigator-assigned NLF severity
scores on a scale of 0–4 for the Juve ´derm-treated NLFs
improved from 2.5–2.7 (moderate to severe) at baseline to
1.2–1.5 (mild) just prior to repeat treatment ([24 weeks)
and 0.7–0.9 (mild) at 4 weeks after repeat treatment. At
48 weeks post-repeat treatment, the mean NLF scores were
1.1–1.3 (mild), and 78–90% of subjects were considered
responders (C1 point improvement). Thus, subjects sus-
tained a total of 18–21 months of wrinkle correction with a
repeat treatment at 6–9 months and needed substantially
less ﬁller (60% less) for repeat treatment than for initial
treatment, indicating that retreatment at this timepoint may
be beneﬁcial to patients.
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Introduction
Dermal ﬁllers serve as one of the most common and useful
treatments for wrinkles and folds. Hyaluronic acid products
are the most widely used in the U.S. and enjoy a favorable
risk/beneﬁt proﬁle. These products provide temporary
correction of the treated area with eventual resorption of
the material and a presumed return to the patient’s pre-
treatment state. Many patients elect to have repeat treat-
ments to maintain the correction; however, the clinical
performance after repeat treatments has not been formally
assessed for most ﬁller products.
The primary objective of this follow-up study was to
evaluate the effectiveness of Juve ´derm injectable gel
(Juve ´derm Ultra, Juve ´derm Ultra Plus, and Juve ´derm 30)
through 1 year after repeat treatment of nasolabial folds
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Zyplast 6–9 months prior to the repeat treatment. An
additional effectiveness objective was to determine if the
volume of Juve ´derm injected at repeat treatment was dif-
ferent from the volume injected during the initial treatment
period and to determine the duration of improvement in
NLF severity after repeat treatment.
Methods
Study design
Upon completion of the pivotal IDE clinical trial for
Juve ´derm 30, Ultra, and Ultra Plus, ﬁve of the original 11
study sites were selected to participate in an extended fol-
low-up evaluation. Sites were selected based on their con-
tinued abilities to participate in the follow-up protocol, their
track record of visit schedule compliance, and the planned
sample size of 150 subjects. No consideration was given to
duration of ﬁller correction in the selection of sites. Subjects
who were eligible and agreed to participate in the follow-up
study signed an informed consent and were followed from 4
through 48 weeks after their repeat treatments. Routine
follow-up visits for effectiveness occurred at 4, 12, and
24 weeks, and an amendment to the protocol added visits at
36 and 48 weeks after repeat treatment. Safety and effec-
tiveness were evaluated at each ofﬁce visit.
Subjects were enrolled in this follow-up study if they had
completed the pivotal study, preferred the Juve ´derm-treated
side(versustheZyplast-treatedside)uponstudyexitandhad
undergone their optional end-of-study (repeat) treatment to
both NLFs on the same day and with the same Juve ´derm
formulationaswasadministeredduringthepivotaltrial.The
repeattreatmentwasadministeredbetween24and36 weeks
(±14 days) after the last treatment in the pivotal study.
Subjects were excluded from the study if they had facial
hair that would interfere with the visual assessments of
NLF severity; had undergone or had plans to undergo any
confounding esthetic procedure such as botulinum toxin
injection, laser resurfacing, etc., in the lower two-thirds of
the face less than 30 days prior to the repeat treatment or at
any time thereafter through the end of the study; had a
clinically signiﬁcant organic disease, condition, illness, or
circumstance that would compromise participation in the
trial; or had received any other investigational treatment
within 30 days prior to study enrollment.
Treatment
During the pivotal trial, subjects were randomized to
receive a single formulation of Juve ´derm in one NLF and
Zyplast collagen in the opposite NLF. The three Juve ´derm
formulations all have a hyaluronic acid concentration of
24 mg/mL and are manufactured using the same technique
(Hylacross technology). Juve ´derm Ultra can be injected
through a 30G needle to allow for more versatility in
treating wrinkles, whereas Juve ´derm 30 is a thicker product
that can be injected through a 27G needle for contouring
deeper folds. Juve ´derm Ultra Plus has the highest degree of
crosslinking of the three ﬁllers to allow extended correction
of deeper folds. An initial treatment and up to two touch-up
treatments at 2-week intervals after initial treatment were
performed to achieve optimal correction in both NLFs and
subjects were followed through 24 weeks after the last
treatment. At the end of the pivotal study, subjects were
asked which treatment they preferred and were subse-
quently unblinded. Subjects were offered repeat treatment
of both NLFs with the original Juve ´derm formulation after
the 24-week visit. For this follow-up study, subjects
remained non-randomized and unblinded.
Investigators determined the appropriate volume of
Juve ´derm needed to obtain optimal correction at the initial,
touch-up, and repeat treatments. The same formulation for
Juve ´derm (Ultra, Ultra Plus, or 30) was used for the initial
andrepeattreatments.Repeattreatmenttookplaceinasingle
session with no limit on injection volume, and no additional
treatments were administered in the follow-up study.
Outcome measures
Effectiveness evaluations were based on NLF severity
assessments and the volume (mL) of ﬁller injected. Injec-
tion volumes were compared for the initial and repeat
treatments, and NLF severity was evaluated throughout the
follow-up periods. The Investigator used the same validated
5-point photographic wrinkle assessment scale (WAS,
Table 1) as was used in the pivotal trial to make live
assessments of the severity of the subject’s NLFs. The scale
represents the spectrum of NLF severity from least to most
severe (range 0–4) and has reference photographs for each
severity grade. The subjects used the same 5-point scale as
the Investigator, except that the subjects made their self
assessments by using the written and numerical descriptions
for reference while examining their NLFs in a mirror.
Table 1 5-Point Wrinkle Assessment Scale for NLF severity
Score Severity descriptions
4 Extreme Very deep wrinkle, redundant fold
(overlapping skin)
3 Severe Deep wrinkle, well-deﬁned edges
(but not overlapping)
2 Moderate Moderately deep wrinkle
1 Mild Shallow, just perceptible wrinkle
0 None No wrinkle
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123The Investigator also evaluated subjects for signs and
symptoms of serious adverse events or unanticipated
adverse events at each study visit. Serum samples were
obtained from subjects at the 4-week post-repeat treatment
visit for IgG antibody testing and comparison with baseline
antibody titers.
Statistical analyses
Effectiveness analyses were performed on the intent-to-
treat population and safety analyses on the ‘‘as treated’’
population. A paired t test was utilized to compare the
volume at initial treatment with the volume at repeat
treatment and the post-treatment NLF severity to baseline.
Clinically signiﬁcant improvement in NLF severity was
deﬁned a priori as C1 point reduction in the WAS score. A
p value of\0.05 was considered statistically signiﬁcant.
Results
Subjects
Of the planned 150 subjects at the ﬁve selected sites, 80
individuals signed consent forms and enrolled in the fol-
low-up study (Fig. 1); 78 subjects completed 24 weeks of
post-repeat treatment follow-up. The revised enrollment
number from 150 to 80 subjects was due to a scarcity of
subjects eligible for the follow-up study (i.e., subjects
chose to delay repeat treatment beyond the 24–36-week
treatment period window allowed in the study because
additional correction was not yet needed). Following
implementation of the protocol amendment adding follow-
up visits at 36 and 48 weeks, 31 subjects who had not
already passed those key timepoints consented to re-enroll,
and 100% completed 48 weeks of post-repeat treatment
follow-up. The primary reason for subjects not consenting
to re-enroll for the extended follow-up was that they had
already passed the 48-week timepoint when the protocol
amendment was implemented.
A majority of the subjects in each cohort were Cauca-
sian and female with a median age between 47 and
53 years (Table 2). More than one-third of subjects in each
cohort had Fitzpatrick Skin Phototypes IV, V, or VI. The
average interval from the last touch-up injection of the
initial treatment until the repeat treatment injection was
201 days (range 149–275 days).
Effectiveness
The injection volume required to achieve optimal correc-
tion was signiﬁcantly less (p\0.0001) at repeat treatment
than at initial treatment (Fig. 2). For the Juve ´derm-treated
NLFs in each treatment group, the median injection vol-
ume for initial treatment was 1.5–1.6 mL, but only
0.5–0.6 mL was required for the repeat treatment depend-
ing upon which Juve ´derm formulation was used. The
median volumes of Zyplast at initial treatment were
2.3–2.8 mL (in each of the three Juve ´derm formulation
arms of the study); these previously Zyplast-treated folds
Completed Juvéderm 12-month 
follow-up study (N=31)
Ultra
n=9
Ultra Plus
n=10
J30
n=12
Entered Juvéderm 12-month 
follow-up study (N=31 b)
Randomized and treated in
Juvéderm 6-month pivotal study
(N=439)
Completed Juvéderm 6-month 
pivotal study (N=423)
Ultra
n=24
Ultra Plus
n=24
J30
n=32
Single retreatment at 6-9 months 
after pivotal study treatment
Entered Juvéderm 6-month 
follow-up study (N=80 a)
Ultra
n=23
Ultra Plus
n=23
J30
n=32
Completed Juvéderm 6-month 
follow-up study (N=78)
Ultra
n=146
Ultra Plus
n=146
J30
n=147
Ultra
n=140
Ultra Plus
n=140
J30
n=143
Fig. 1 Subject disposition ﬂowchart.
aPlanned enrollment was 150
subjects. The primary reason that 150 was not achieved was that
subjects were ineligible because they chose to delay repeat treatment
beyond the window allowed in the Juve ´derm follow-up study
protocol.
bThe primary reason for subjects not re-enrolling in the
extended portion of the Juve ´derm follow-up study was that they had
already passed the 6-month timepoint when the protocol amendment
was implemented
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123required a median amount of 1.0–1.2 mL of Juve ´derm to
achieve optimal correction at repeat treatment.
Mean Investigator-assigned NLF severity scores for the
Juve ´derm-treated NLFs remained improved from 2.5-2.7
(moderate to severe) at baseline to 1.2–1.5 (mild) just prior
to repeat treatment (greater than 24 weeks) (Fig. 3). After
repeat treatment, the mean NLF scores at 4 weeks were
0.7–0.9 (mild), similar to the mean scores seen after com-
pletion of the initial treatment. At 48 weeks post-repeat
treatment, the mean NLF WAS scores ranged from 1.1 to
1.3 (mild). Subject assessments paralleled those of Inves-
tigators, with improvement from mean scores of 2.3–2.5 at
baseline to 0.8–0.9 at 48 weeks post-repeat treatment.
The mean improvement in NLF severity remained
clinically signiﬁcant (C1 point) from 4 weeks after initial
treatment through 48 weeks after repeat treatment. Thus,
subjects sustained a total of 18–21 months of wrinkle
correction with a repeat treatment at 6–9 months (Fig. 4).
Furthermore, a full 78–90% of subjects were responders
(C1 point WAS improvement) at 48 weeks post-repeat
treatment (Fig. 5), and the long-term results showed a
smooth, natural looking wrinkle correction (Fig. 6).
Safety and tolerability
No serious or unanticipated adverse events were reported.
One subject had positive serum IgG antibody titers at
Table 2 Subject demographics (ITT population)
Juve ´derm Ultra (N = 24) Juve ´derm Ultra Plus (N = 24) Juve ´derm 30 (N = 32)
N Percentage N Percentage N Percentage
Gender
Female 21 88 22 92 28 88
Male 3 13 2 8 4 13
Age (years)
Median 48.5 47.0 52.5
Range 32–75 35–74 32–66
Ethnicity
Caucasian 14 58 17 71 19 59
African American 4 17 5 21 9 28
Hispanic 4 17 2 8 3 9
Asian 2 8 0 0 0 0
Other 0 0 0 0 1 3
Fitzpatrick skin phototype
I0 0 3 1 3 0 0
II 4 17 5 22 5 15
III 10 42 6 26 8 24
IV 5 21 5 22 10 30
V 4 17 4 17 6 19
VI 1 4 1 4 3 9
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Fig. 3 Mean NLF severity score assessed by Investigators
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12324 weeks after initial and 4 weeks after repeat treatment,
but no clinical signs or symptoms of hypersensitivity.
Discussion
The impermanent nature of most dermal ﬁllers and the
progressive nature of skin aging require that the patient
undergoes repeat treatments to maintain the desired cor-
rection. Typically, these are done when the patient notices
that the prior correction has declined, additional correction
is desired, and/or when ﬁnances allow. This study dem-
onstrates that a repeat treatment performed at 6–9 months
results in a prolonged beneﬁt with a dramatic reduction in
the volume of material required to achieve optimal cor-
rection and thus less impact on the patient’s ﬁnancial
resources. Accordingly, it is likely in the patient’s best
interest for the physician to recommend re-injections at this
timepoint even if signiﬁcant correction is still seen from the
initial injections. Re-injecting while some correction
remains enables the patient to enjoy a very prolonged result
which requires only a fraction of the amount of material
required for the initial injections. Injecting a smaller vol-
ume while a signiﬁcant correction remains also yields less
dramatic changes in the appearance over time, leading to a
natural appearance and making the fact that one has had
treatments less noticeable to the public, which for many
patients is a beneﬁt. These effects for the 6–9-month re-
injection appear to be speciﬁc to the Juve ´derm products,
however, as the subjects who were initially treated with
Zyplast required substantially higher volumes of Juve ´derm
at their retreatment compared to subjects who had initially
received hyaluronic acid.
Precisely, why such substantial differences are seen with
re-injection is unknown. The elimination kinetics of
crosslinked hyaluronic acid are not well characterized.
Data from a single subject using high spatial resolution T2
parametric magnetic resonance images showed that very
small amounts of injected hyaluronic acid can be detected
4–9 months after injection into the forearm [2]. Wang et al.
[5] demonstrated increased collagenesis in response to
tissue expansion after dermal ﬁller injection. This concept
is further supported by a study of 63 subjects who received
repeat treatment with Restylane in which Narins et al. [4]
showed longevity of hyaluronic acid ﬁller injection after
retreatment and speculated that maintaining the tension
from the tissue expansion stimulated collagen production
and inhibited collagen breakdown.
It remains unclear whether the persistence of correction
seen with longer follow-up in non-permanent ﬁller mate-
rials is due to retained material or another phenomenon.
While the actual mechanism of action for persistence is not
clearly elucidated, the clinical endpoints seen in the
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123grading scales used in studies of dermal ﬁllers have been
shown to be reproducible and reliable [1, 3]. The results are
real, regardless of how they occur.
Hyaluronic acid (as hyaluronan) is found in many tis-
sues of the body and is generally considered innocuous
when injected as a cross-linked polymer. Any time there
are repeated exposures to foreign materials, the possibility
of sensitization becomes a concern. In this study, only a
single subject was noted to develop antibodies directed
towards hyaluronic acid, and no clinical ﬁndings consistent
with allergy or sensitization were noted in this subject.
This study was conducted as an addendum to the pivotal
study for the approval of the Juve ´derm family of products
in the U.S. While the number of subjects participating in
this longer-term study is smaller than in the original study,
the sample size was large enough to obtain statistically
signiﬁcant results for the study endpoints. Although three
formulations of Juve ´derm (Juve ´derm Ultra, Juve ´derm Ultra
Plus, and Juve ´derm 30) were studied, only two of these
formulations (Juve ´derm Ultra and Ultra Plus) are com-
mercially available in the U.S.
Conclusions
The Juve ´derm family of ﬁllers provides clinically signiﬁ-
cant improvement in the severity of nasolabial folds
through 18–21 months in subjects who receive a repeat
treatment at 6–9 months. Subjects need substantially less
ﬁller (60% less) for repeat treatment than for initial treat-
ment, indicating that retreatment at this timepoint may be
beneﬁcial to the patient in terms of reduced price for
smaller subsequent treatments and less dramatic swings in
appearance. The Juve ´derm ﬁllers demonstrated effective-
ness and safety across all skin types, as well as in both male
and female subjects. Their extended persistence, resulting
in less frequent treatments, combined with the natural look
and feel of the skin post-treatment can be expected to
produce a high level of patient satisfaction.
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